No studies have investigated whether GCA disease activity can be monitored by FDG-PET/CT in patients on GC-sparing drugs such as tumor necrotic factor α (TNF-α) blocking agents for TA or interleukin-6 receptor blockade (tocilizumab) for GCA. Here, IL6R is linked to temporal arteritis.